Travis C. Mickle

Co-Founder & President at KemPharm

Dr. Mickle co-founded KemPharm Inc. in 2006 with the discovery of the company’s LAT® (Ligand Activated Therapy) prodrug technology. As President and Board Member he oversees KemPharm’s scientific strategy and is instrumental in the ongoing development of the company’s pipeline of proprietary prodrugs.

Prior to founding KemPharm, Dr. Mickle served as Director of Drug Discovery and CMC at New River Pharmaceuticals where he was the principal inventor of Vyvanse®, a prodrug of amphetamine for the treatment of attention deficit hyperactivity disorder (ADHD). Today, Vyvanse is the branded market share leader in the estimated $17 billion plus ADHD market. The success of Vyvanse along with a robust pipeline of prodrugs targeting ADHD, pain and thyroid dysfunctions, which Dr. Mickle was responsible for creating, led to New River Pharmaceuticals being acquired by Shire Pharmaceuticals, PLC for $2.6 billion.

Links

Timeline

  • Co-Founder & President

    Current role

View in org chart